Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brenda Sandburg
NIH Director Francis Collins describes evolution of existing collaborations and how the two agencies might facilitate development of gene therapy, such as by having a common template for regulatory review.
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.
Justices question why it took 170 years for the patent office to seek attorneys' fees from patent applicants who challenge its decisions in district court; USPTO acknowledges the delay is 'atmospherically unhelpful.'
There are "tremendous concerns" about potential abuse of biomarkers to diagnose pain, Stanford University researcher tells FDA Science Forum.
Four distributors and Walgreens also remain defendants; court to consider Teva's motion to dismiss if the trial results in a judgement against its subsidiaries. Seven-week trial could include 215 witnesses and 21,000 exhibits.